Singapore eDevelopment's Global BioLife confirms 100% Repellency of 3F Mosquito Fragrance
SINGAPORE, Nov 01, 2017 - (ACN Newswire) - Singapore Exchange-listed Singapore eDevelopment Ltd ("SeD") announced today that its U.S. biomedical subsidiary Global BioLife Inc. has completed development and testing of mosquito deterring technologies including fragrances, paints, and fabric.
3F Mosquito, a fragrance made up of specialized oils sourced from botanicals that mosquitoes avoid, has shown 100% repellency against mosquitoes in laboratory testing. Global BioLife contracted U.S-based Snell Scientifics LLC ("Snell") in Meansville, Georgia to conduct the mosquito studies for the mosquito deterring technologies.
In August 2017 SeD announced that Global BioLife was collaborating with U.S-based Chemia Corporation to develop a suite of fragrances for medical applications referred to as 3F (Functional Fragrance Formulation). Global BioLife entered into further collaboration with Chemia to co-develop 3F Mosquito for laundry detergents, shampoos and lotions.
3F Mosquito products are based on extensive research of botanical oils which possess mosquito repelling properties. When 3F is infused into products such as detergents, shampoos, and lotions, consumers will be provided with multiple layers of protection against mosquito bites, a revolutionary alternative to traditional mosquito repellents.
"Chemia is very excited to introduce these sustainable and tested fragrances to provide natural alternatives to protecting consumers from the risk of mosquito transmitted diseases," said Mr. Thomas A. Meyer, Chemia's Vice-President of Innovation and Sustainability.
The uniquely-designed mosquito deterring paints and functional fabric both deter mosquitoes by chemical-free photonic means; a wavelength of light is emitted that mosquitoes avoid. Snell reported that Global BioLife's photonic mosquito paints and mosquito fabric both exhibit degrees of repellency effective against mosquitoes.
Global BioLife and Chemia have designed the mosquito deterring fabric for use in outdoor apparel, hats, tents, and other camping gear. The mosquito deterring paints were designed as exterior paints for homes as well as commercial applications. These new mosquito deterring technologies are non-chemical methods of repelling mosquitoes for consumers. Mr. Daryl Thompson, Global BioLife Director of Scientific Initiatives, said "The objective in the design of 3F Mosquito was to identify and create a suitable formula that was both pleasant and would excel in protective abilities against mosquitoes. These oils are scientifically proven to affect mosquitoes' receptors, essentially making the mosquito blind to your presence. 3F offers a pleasant scent while providing layers of protection to keep people safe from mosquito bites."
The market for safe mosquito repellents and deterrents is growing as the risk of Zika grows. The most vulnerable group of our population at highest risk for Zika infection may be pregnant women, because of their avoidance and dislike of products containing Deet. The US Center for Disease Control has released multiple statements that the use of Deet is safe, however pregnant women continue to be hesitant to use Deet-containing products.
Dr. Peggy Tang, Global BioLife's CEO, commented: "We expect that these new techniques for fighting mosquito bites will be very appealing to consumers. We are providing unique and useful products, free of harsh chemicals. Due to the perceived toxicity of Deet and the avoidance of chemicals by consumers, Global BioLife's chemical-free products will have a direct advantage over traditional mosquito repellents."
"Biomedical science has become increasingly vital. Global BioLife is proud to be taking steps to provide solutions to issues that have been plaguing the biomedical field for decades. This collaboration marks one of the first steps in actively changing the game of healthcare," said SeD and Global BioLife Executive Chairman Mr. Chan Heng Fai.
Mr. Thomas Meyer added: "This groundbreaking partnership with Global BioLife sets the stage for a steady stream of innovative fragrances that feature functional properties in various consumer product applications."
In addition to 3F Mosquito, Global BioLife is working with Chemia on the formulation of additional 3F fragrances to fight stress and anxiety and 3F for anti-viral medical applications.
About Global BioLife Inc.
Global BioLife Inc. ("GBLI") is a 80%-held direct subsidiary of Global BioMedical Inc., which is a wholly-owned direct subsidiary of Singapore BioMedical Pte. Ltd., which in turn is a wholly-owned direct subsidiary of Singapore eDevelopment Limited, a company listed on the Singapore Exchange. The remaining shareholding of Global BioLife Inc. is held by Global Research and Discovery Group Scientific LLC ("GRDGS") and Australian Exchange-listed Holista CollTech Limited ("Holista") in equal proportions of 10% each.
With an aging population and a growing focus in healthcare issues, biomedical science has become increasingly vital. GBLI strives to leverage its scientific know-how and intellectual property rights to provide solutions that have been plaguing the biomedical field for decades. GBLI is also collaborating with its partners to develop second generation mosquito defence technologies, which are DEET alternatives, to protect against mosquito transmitted diseases such as Zika and Dengue. For more information, please visit: http://www.globalbiolife.com About Chemia Corporation
Chemia Fragrance and Flavor provides high quality, cost effective fragrances to the manufacturers of personal care, household and industrial & institutional products. For more information, please visit: http://www.chemiacorp.com.
About Singapore eDevelopment Limited
Incorporated on 9 September 2009 and listed on the Singapore Exchange in July 2010, Singapore eDevelopment Limited is involved in (i) property development and investments primarily in the United States and Western Australia; (ii) information technology-related businesses; (iii) development, research, testing, manufacturing, licensing and distribution of biomedical products; and (iv) investment activities. For more information, please visit: www.SeD.com.sg or email contact@sed.com.sg.
Source: Alset International Ltd Sectors: BioTech, Healthcare & Pharm, Cosmetics, Spec.Chem
Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
Latest Release
"LEQEMBI" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea Nov 28, 2024 16:26 JST
| Hitachi High-Tech Launches DCR Etch System 9060 Series, Supporting Isotropic Etching of Advanced 3D Devices at the Atomic Level Nov 28, 2024 11:31 JST
| MHI Delivers Final Trainset of Automated Guideway Transit System "2020 Series" to Saitama New Urban Transit Nov 28, 2024 10:08 JST
| TOPVISION Launches Prospectus for Listing Transfer from LEAP to the ACE Market Nov 27, 2024 05:53 JST
| TOYOTA GAZOO Racing FULLY PREPARED FOR DAKAR 2025 Nov 26, 2024 17:55 JST
| Eisai Signs Research Collaboration Agreement with The National Center of Neurology and Psychiatry to Initiate Apolipoprotein E Genetic Testing in the "AD-DMT Registry" in Japan Nov 26, 2024 15:50 JST
| Fujitsu develops Policy Twin, a new digital twin technology to maximize effectiveness of local government policies for solving societal issues Nov 26, 2024 10:51 JST
| TOYOTA GAZOO Racing reinforces WRC line-up with youth and experience for 2025 Nov 25, 2024 17:10 JST
| Toyota Submits Progress Report on Recurrence Prevention Measures Nov 25, 2024 15:43 JST
| TOPVISION Launches Prospectus for Transfer Listing from LEAP to the ACE Market Nov 25, 2024 15:00 JST
| MHI Thermal Systems Receives Order from Aisan Industry for Aquifer Thermal Energy Storage System for Its New Anjo Plant Nov 25, 2024 14:18 JST
| Oracle Red Bull Racing Driver Max Verstappen Wins Fourth Consecutive F1 Drivers' World Championship Nov 25, 2024 11:55 JST
| Kaplan Fox & Kilsheimer LLP Alerts Investors to a Securities Class Action Against Humacyte, Inc. (HUMA) - Deadline is January 17, 2025 Nov 22, 2024 11:00 JST
| NaaS Q3 2024 Recap: Strategic Shifts and Tech Innovations for Growth Nov 21, 2024 22:59 JST
| Honda Unveils Demonstration Production Line for All-Solid-State Batteries Located in Sakura City, Tochigi Prefecture, Japan Nov 21, 2024 15:35 JST
| Deadline to Lead in Securities Fraud Lawsuit Against Humacyte, Inc. (HUMA) is January 17, 2025 - Contact Kaplan Fox & Kilsheimer LLP Nov 21, 2024 09:00 JST
| ALL Study Groups Using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria's 12-Week GLP-1, Diabetes Animal Study Nov 20, 2024 23:05 JST
| Start of Demonstration Test of Two-Phase Direct-to-Chip Cooling in the Air-Cooled Data Center Nov 20, 2024 15:30 JST
| Rozebalamin for Injection 25mg (Mecobalamin) for Amyotrophic Lateral Sclerosis Launched in Japan Nov 20, 2024 11:51 JST
| Anticancer Agent "TASFYGO Tablets 35mg" (Tasurgratinib Succinate) Launches in Japan for Biliary Tract Cancer with FGFR2 Gene Fusion or Rearrangements Nov 20, 2024 10:24 JST
|
More Latest Release >>
|